论文部分内容阅读
To assess the efficacy of the anti- TNF monoclonal antibody infliximab in uveitis patients without clinically evident ocular inflammation and impaired visual acuity because of chronic cystoid macular edema (CME). Prospective, noncomparative, interventional case series. Patients with refractory CME (14 eyes, mean duration of 14 months), associated with intermediate uveitis (n=6), Adamantiades- Behcet disease (n=2), adult- type vascular pseudotumor (n=1), and HLAB27+ - related uveitis (n =1) received an intravenous infliximab infusion (5 mg/kg); five patients were retreated after 1 month. Macular thickness, measured by ocular coherence tomography, was reduced from 428 ± 138 μ m to 219 ± 51 μ m at 2 months postbaseline (P=. 000 1), while visual acuity increased from 0.41 ± 0.18 to 0.83 ± .0.17 (P < .000 01). Anatomic and functional improvement was sustained at 6 months in all. No ocular or extra- ocular side effects were noted. These promising results suggest that TNF may play an important pathogenetic role in chronic CME, thus, a controlled trial is warranted.rights reserved.
To assess the efficacy of the anti-TNF monoclonal antibody infliximab in uveitis patients without clinically evident ocular inflammation and impaired visual acuity because of chronic cystoid macular edema (CME). Prospective, noncomparative, interventional case series. Patients with refractory CME (14 eyes, mean duration of 14 months), associated with intermediate uveitis (n = 6), Adamantiades- Behcet disease (n = 2), adult- type vascular pseudotumor (n = 1), and HLAB27 + Macular thickness, measured by ocular coherence tomography, was reduced from 428 ± 138 μm to 219 ± 51 μm at 2 months postbaseline (P = .000 1), while visual acuity increased from 0.41 ± 0.18 to 0.83 ± .0.17 (P <.000 01). Anatomic and functional improvement was sustained at 6 months in all. No ocular or extra-ocular side effects were noted. These promising results suggest that TNF may play an im portant pathogenetic role in chronic CME, thus, a controlled trial is warranted.rights reserved.